JPMorgan’s $48 target on TNGX

TNGX Tango Therapeutics Inc

$23.8 → $48 (+102%) by Oct 2027

Overweight · reiterates · said Oct 13, 2026 · 12-month default horizon

Open: judged on the close on Oct 13, 2027

The article this target came from

JPMorgan reiterates Tango Therapeutics stock rating ahead of ESMO data

Investing.com · Oct 13, 2026

JPMorgan reiterated an Overweight rating and $48.00 price target on Tango Therapeutics Inc. (NASDAQ:TNGX).

JPMorgan’s track record → Tango Therapeutics Inc →

A fact about what JPMorgan published, as reported by Investing.com, not a recommendation from Dalsna Finance; JPMorgan is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.